Search Page

1

Cite

Share

Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction.

Haltern G, Peiniger S, Bufe A, Reiss G, Gülker H, Scheffold T. Haltern G, et al. Among authors: reiss g. Am J Cardiol. 2010 Jan 1;105(1):1-9. doi: 10.1016/j.amjcard.2009.08.645. Epub 2009 Nov 13. Am J Cardiol. 2010. PMID: 20102882

Cite

Share

2

Cite

Share

Improving biliary stent patency by the use of stent coating - a prospective randomized porcine study.

Weickert U, Weddeling S, Subkowski T, Eickhoff A, Reiss G. Weickert U, et al. Among authors: reiss g. Z Gastroenterol. 2016 Jul;54(7):629-33. doi: 10.1055/s-0042-101771. Epub 2016 Jul 18. Z Gastroenterol. 2016. PMID: 27429099 Clinical Trial. English.

Cite

Share

3

Cite

Share

A comparative scanning electron microscopic study of biliary and pancreatic stents.

Weickert U, Zimmerling S, Eickhoff A, Riemann JF, Reiss G. Weickert U, et al. Among authors: reiss g. Z Gastroenterol. 2009 Apr;47(4):347-50. doi: 10.1055/s-2008-1027926. Epub 2009 Apr 8. Z Gastroenterol. 2009. PMID: 19358060

Cite

Share

4

Cite

Share

Optimizing biliary stent patency by coating with hydrophobin alone or hydrophobin and antibiotics or heparin: an in vitro proof of principle study.

Weickert U, Wiesend F, Subkowski T, Eickhoff A, Reiss G. Weickert U, et al. Among authors: reiss g. Adv Med Sci. 2011;56(2):138-44. doi: 10.2478/v10039-011-0026-y. Adv Med Sci. 2011. PMID: 21940267

Cite

Share

5

Cite

Share

Does heparin coating reduce encrustation of biliary plastic endoprostheses? A prospective randomized trial.

Weickert U, Reiss G, Eickhoff A. Weickert U, et al. Among authors: reiss g. Scand J Gastroenterol. 2013 Mar;48(3):380. doi: 10.3109/00365521.2012.758772. Epub 2013 Jan 10. Scand J Gastroenterol. 2013. PMID: 23301928 No abstract available.

Cite

Share

6

Cite

Share

3D reconstruction of SEM images by use of optical photogrammetry software.

Eulitz M, Reiss G. Eulitz M, et al. Among authors: reiss g. J Struct Biol. 2015 Aug;191(2):190-6. doi: 10.1016/j.jsb.2015.06.010. Epub 2015 Jun 11. J Struct Biol. 2015. PMID: 26073969

Cite

Share

7

Cite

Share

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.

Portal-Celhay C, Forleo-Neto E, Eagan W, Musser BJ, Davis JD, Turner KC, Norton T, Hooper AT, Hamilton JD, Pan C, Mahmood A, Baum A, Kyratsous CA, Kim Y, Parrino J, Kampman W, Roque-Guerrero L, Stoici R, Fatakia A, Soo Y, Geba GP, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM; COVID-19 Phase 2 Dose-Ranging Study Team. Portal-Celhay C, et al. JAMA Netw Open. 2022 Aug 1;5(8):e2225411. doi: 10.1001/jamanetworkopen.2022.25411. JAMA Netw Open. 2022. PMID: 35969402 Free article. Clinical Trial.

Cite

Share

8

Cite

Share

Considering the Role of Extracellular Matrix Molecules, in Particular Reelin, in Granule Cell Dispersion Related to Temporal Lobe Epilepsy.

Leifeld J, Förster E, Reiss G, Hamad MIK. Leifeld J, et al. Among authors: reiss g. Front Cell Dev Biol. 2022 Jun 6;10:917575. doi: 10.3389/fcell.2022.917575. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35733853 Free PMC article. Review.

Cite

Share

9

Cite

Share

Thickness-Varied Carbon Nanomembranes from Polycyclic Aromatic Hydrocarbons.

Qi Y, Westphal M, Khayya N, Ennen I, Peters T, Cremer J, Anselmetti D, Reiss G, Hütten A, Gölzhäuser A, Dementyev P. Qi Y, et al. Among authors: reiss g. ACS Appl Mater Interfaces. 2022 Feb 23;14(7):9433-9441. doi: 10.1021/acsami.1c22406. Epub 2022 Feb 14. ACS Appl Mater Interfaces. 2022. PMID: 35157431

Cite

Share

10

Cite

Share

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939. JAMA. 2022. PMID: 35029629 Free PMC article. Clinical Trial.

Cite

Share